Salvatore Nieddu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Salvatore Nieddu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Angela Corona
University of Cagliari
2 shared publications - Annalaura Paulis
Department of Life and Environmental Science, University of Cagliari, Cagliari, Italy
2 shared publications - Enzo Tramontano
Laboratory of Molecular Virology, Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy
2 shared publications - Paolo Malune
Department of Life and Environmental Sciences, Biomedical Section, Laboratories of Molecular Virology, E Building, University of Cagliari, University Campus, S.P. 8, Monserrato, CA, 09042, Italy
2 shared publications Alessandra Crusco
Axxam SpA Openzone, Via Meucci 3, Bresso, 20091, Milan, Italy
1 shared publication- Alessia Onali
Department of Life and Environmental Sciences, Drug Sciences Section, Laboratories of Synthesis and CADD, University of Cagliari, A Building, University Campus, S.P. 8, Monserrato, CA, 09042, Italy
1 shared publication
Latest Publications
- Open Access
- 5 May 2026
- Published by Elsevier in SSRN Electronic Journal
A combination of MD derived pharmacophores and structure-based strategy identifies broad-spectrum allosteric inhibitors of NS2B-NS3 proteases in Zika and West Nile Viruses
Starting from the crystal structure of a Zika virus (ZIKV) NS2B-NS3 protease with bound allosteric inhibitor, we generated dynamic pharmacophore models derived from representative molecular dynamics (MD) conformations to capture key interaction patterns. These models guided a pharmacophore-based virtual screening of commercial libraries, including commercial compounds and approved drugs, enabling the rapid selection of virtual hit compounds. Biochemical evaluation identified several inhibitors, with the antiretroviral drug Nelfinavir emerging as the most promising compound. Nelfinavir displayed the strongest inhibition of ZIKV and West Nile virus (WNV) proteases and showed antiviral activity in cell-based assays, with EC50 values of 1.79 ± 0.01 µM on ZIKV and 3.01 ± 1.25 µM in WNV, supporting its relevance as a repositionable scaffold for modulation of ZIKV and WNV infections. The activity observed across flavivirus proteases highlights the value of targeting conserved allosteric regions. Overall, this integrated computer aided drug design (CADD) strategy demonstrates the power of dynamic, structure-based pharmacophores to uncover novel allosteric inhibitors and accelerate antiviral drug repurposing.
- 5 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA combination of MD derived pharmacophores and structure-based strategy identifies broad-spectrum allosteric inhibitors of NS2B-NS3 proteases in Zika and West Nile Viruses
Starting from the crystal structure of a Zika virus (ZIKV) NS2B-NS3 protease with bound allosteric inhibitor, we generated dynamic pharmacophore models derived from representative molecular dynamics (MD) conformations to capture key interaction patterns. These models guided a pharmacophore-based virtual screening of commercial libraries, including commercial compounds and approved drugs, enabling the rapid selection of virtual hit compounds. Biochemical evaluation identified several inhibitors, with the antiretroviral drug Nelfinavir emerging as the most promising compound. Nelfinavir displayed the strongest inhibition of ZIKV and West Nile virus (WNV) proteases and showed antiviral activity in cell-based assays, with EC50 values of 1.79 ± 0.01 µM on ZIKV and 3.01 ± 1.25 µM in WNV, supporting its relevance as a repositionable scaffold for modulation of ZIKV and WNV infections. The activity observed across flavivirus proteases highlights the value of targeting conserved allosteric regions. Overall, this integrated computer aided drug design (CADD) strategy demonstrates the power of dynamic, structure-based pharmacophores to uncover novel allosteric inhibitors and accelerate antiviral drug repurposing.
- Open Access
- 18 February 2025
- Published by Elsevier in Antiviral Research
- Vol. 237, 106119
The efficiency of high-throughput screening (HTS) and in-silico data analysis during medical emergencies: Identification of effective antiviral 3CLpro inhibitors
- 18 February 2025
- Published by Elsevier in Antiviral Research
- Vol. 237, 106119
Open AccessThe efficiency of high-throughput screening (HTS) and in-silico data analysis during medical emergencies: Identification of effective antiviral 3CLpro inhibitors